Amgen Soft on FDA Data (AMGN)

Posted in pre-market 
October 19th, 2009

Amgen Inc. (NASDAQ: AMGN) was on deck for an FDA decision on its Prolia bone drug.  The FDA has effectively delayed its decision to approve the drug with a request for more information.  The FDA wants to know how the company will monitor patients using Prolia and it also wants Amgen to develop a strategy to evaluate the risks of Prolia.  As of 8:42 AM EST we have shares down 3% at $59.30 on over 540,000 shares.  Average volume is almost 7.5 million shares, and this is already better than some of the pre-market trades indicated earlier. JON OGG

Comments are closed